Market Overview

Genzyme's Once-Daily, Oral AUBAGIO Approved in Australia

Related SNY
UPDATE: Sanofi Posts Upbeat Q2 Earnings, Lifts Profit Outlook
Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield
Allergan Reportedly Seeks Alternate Suitor (Fox Business)

Genzyme, a Sanofi company, (NYSE: SNY) announced today that the Australian Therapeutic Goods Administration (TGA) has approved AUBAGIO^® (teriflunomide) 14 mg as a new once-daily, oral treatment indicated for patients with relapsing forms of multiple sclerosis (MS). The TGA approval will enable health professionals to prescribe AUBAGIO 14 mg in Australia, which is now the second country to gain marketing authorization for the treatment, following FDA approval in September.

Posted-In: News

 

Most Popular

Related Articles (SNY)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters

Benzinga Professional